GO was also approved by the European Medicines Agency (EMA) in February 2018 in combination therapy with DNR and AraC for the treatment of patients ≥ 15 years old with previously untreated, de novo CD33 + AML, except acute promyelocytic leukemia (APL) [16]. This evidence concerns the gene CD33 and acute promyelocytic leukemia.